Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com

StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a sell rating to a hold rating in a report published on Monday morning. Several other brokerages also recently issued reports on BPMC. SVB Securities reduced their price objective on Blueprint Medicines from $45.00 to $38.00 in a research note on Friday, February 24th. […]

Related Keywords

Blackrock ,United Kingdom General ,United Kingdom ,Cambridge ,Cambridgeshire ,Wellington ,New Zealand General ,New Zealand ,Stifel Nicolaus ,Christopherk Murray ,Brian Druker ,Chris Varma ,Nicholasb Lydon ,Christina Rossi ,Raymond James ,Securities Exchange Commission ,Blueprint Medicines Corp ,Blackrock Inc ,Norges Bank ,Morgan Stanley ,Wellington Management Group ,Marshall Wace ,Blueprint Medicines ,Get Rating ,Moderate Buy ,Medicines Stock Down ,Exchange Commission ,Street Corp ,Management Group ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Upgrade ,Stocknews Com ,